Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.32 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23571253 | 1.00 | CYP11B1 (0.33) | CYP11B1CYP11B2CYSLTR2CYSLTR1NR1I2 | |
| SCHEMBL21361275 | 0.85 | GPR84 (0.35) | CYP11B1CYP11B2 | |
| SCHEMBL21859724 | 0.80 | CYP11B1 (0.31) | CYP11B1CYP11B2CYSLTR2CYSLTR1NR1I2 | |
| SCHEMBL25027678 | 0.79 | CYP11B1 (0.37) | CYP11B1CYP11B2 | |
| SCHEMBL25452117 | 0.77 | CYSLTR2 (0.39) | CYSLTR2CYSLTR1 | |
| SCHEMBL25452699 | 0.75 | CYSLTR2 (0.38) | CYP11B1CYP11B2CYSLTR2CYSLTR1 | |
| SCHEMBL26463849 | 0.74 | CYP11B1 (0.38) | CYP11B1CYP11B2 | |
| SCHEMBL18635979 | 0.73 | TDP1 (0.38) | CYSLTR2CYSLTR1NR1I2 | |
| SCHEMBL18855230 | 0.73 | TDP1 (0.38) | CYSLTR2CYSLTR1NR1I2 | |
| SCHEMBL22307857 | 0.73 | NR1I2 (0.36) | NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188843-A1 | QUINOLINE COMPOUNDS AND THEIR PREPARATION AND USE AS ANTIMALARIAL AGENTS | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188843-A1 | QUINOLINE COMPOUNDS AND THEIR PREPARATION AND USE AS ANTIMALARIAL AGENTS | GLS2, RECQL, PYGL | CYP11B1 17/4885CYP11B2 22/4885CYSLTR2 2729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.